InnoSer and TheraIndx announce their strategic partnership to better serve pharmaceutical and biomedical companies worldwide. Jan Bartels, the CEO of InnoSer, states: “Both companies offer unique service portfolios and bring a lot of aligned added value to our global customer base. We are very excited about the opportunities this partnership will generate. Especially the need of our customers in high quality pharmacology and toxicology services and the unique range of animal models of diseases offered by TheraIndx will accelerate the drug development of our customers.” Sundaresh Babu, the CEO of TheraIndx, agrees to Jan Bartels: ”InnoSer values developing and using in-vitro models that mimic human systems. TheraIndx has globally acclaimed animal model expertise to complement in-vitro capabilities of InnoSer. Together, InnoSer and TheraIndx bring a complete range of drug discovery services.”
About InnoSer
Founded in 2012, InnoSer is an innovative and dynamic contract research organization (CRO) supporting discovery and preclinical development of drugs. It provides quality services to pharmaceutical and biotechnology clients in different therapeutic fields. These include PDXO screening platform for oncology, ADPKD mouse model for nephrology, and validated brain organoid models for Parkinson’s for neurodegenerative diseases. InnoSer’s service portfolio also includes in-vitro pyrogenicity testing and genetically engineered mice model services like colony management, cryopreservation, sanitation/rederivation and pathology.
About TheraIndx
Founded in 2014, TheraIndx is a fast growing preclinical CRO , offering modular and integrated drug discovery solutions for pharma and biotech companies spanning across 5 continents. Its service offerings include a wide range of animal models of disease such as oncology, infection, metabolic disorders, wound healing and auto immune disorders integrated with biomarkers, DMPK and Toxicology studies. TheraIndx’s management team has several decades of collective experience in drug discovery and development which includes in vitro biology, DMPK, pharmacology and toxicology. TheraIndx’s validated animal models for critical therapeutic areas like complicated UTI and thigh infection have been presented and recognised at global platforms like ECCMID & ASM conferences.